Testing a supplement for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a supplement called Neuroaid II can help people with mild to moderate Alzheimer's disease. It is a pill taken alongside your usual Alzheimer's treatments, and the study aims to see if it can slow down memory decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old and have a diagnosis of Alzheimer's disease.
- A blood test must show a specific Alzheimer's marker (called ptau217) at a level of at least 0.471 pg/mL.
- Your memory and thinking symptoms should be in the mild to moderate range (a score between 10 and 26 on a standard test called MMSE).
- You need a study partner (like a family member or friend) who can spend at least 8 hours a week with you and attend study visits or be available by phone.
- You cannot be taking certain Alzheimer's medications or supplements (like Ginkgo biloba or piracetam) at the start of the study.
- You must not have other brain conditions (like Parkinson's disease, epilepsy, or severe stroke damage) that could explain your memory problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This trial is testing an experimental medicine called QLH2405 in two groups: healthy volunteers (to check safety) and people with mild memory problems due to Alzheimer's. If you qualify, the study may help find out if this new treatment is safe and could slow down memory decline.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This trial tests an experimental pill, T3D-959, for people with mild-to-moderate Alzheimer's disease. The goal is to see if it can help slow memory and thinking decline. You would need to visit the clinic regularly for check-ups and memory tests.
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.